Artiva Biotherapeutics, Inc. (ARTV)
(Delayed Data from NSDQ)
$2.76 USD
+0.12 (4.55%)
Updated Aug 8, 2025 03:59 PM ET
After-Market: $2.76 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ARTV 2.76 +0.12(4.55%)
Will ARTV be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ARTV based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ARTV
AFMD Stock Down Despite FDA's RMAT Status for Lymphoma Therapy
ARTV: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for ARTV
Artiva Biotherapeutics GAAP EPS of -$0.87 misses by $0.06
Artiva Biotherapeutics files $300M mixed securities shelf
12 Health Care Stocks Moving In Wednesday's After-Market Session
Artiva Biotherapeutics Approves Equity Plan Amendment
Promising Advancements and Financial Strength Position Artiva Biotherapeutics for Significant Upside